生物疗法与以色列风湿性关节炎患者的恶性瘤有关:基于人口的研究
Ella Katony Eizenstat1, Fadi Hassan1,2, Avivit Golan Cohen3,4
1Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.
International journal of rheumatic diseases
|June 3, 2023
概括
生物修饰性抗风湿药物 (bDMARDs) 可能会增加以色列类风湿性关节炎 (RA) 患者的恶性瘤风险. 黑色素瘤和非黑色素瘤皮肤癌是最常见的,这表明在这个人群中存在潜在的倾向.
科学领域:
- 类风湿病学 类风湿病学
- 在瘤学瘤学.
- 流行病学 流行病学
背景情况:
- 类风湿性关节炎 (RA) 是一种慢性自身免疫性疾病.
- 生物疾病修饰性抗风湿药物 (bDMARDs) 用于管理RA.
- bDMARDs与恶性瘤风险之间的关联需要进一步调查.
研究的目的:
- 调查bDMARD使用与以色列RA患者恶性瘤风险之间的关联.
- 为了确定可能与bDMARDs相关的特定类型的恶性瘤.
- 探索RA患者对某些癌症的潜在倾向因素.
主要方法:
- 使用Leumit医疗保健服务数据库 (2000-2017年) 进行的回顾性队列研究.
- 纳入/排除标准用于识别符合条件的RA患者.
- 考克斯回归分析以评估基线变量,bDMARD/DMARD消费和恶性瘤发生之间的关联.
主要成果:
- 在4268名RA患者中,688名 (16.12%) 患有恶性瘤.
- 黑色素瘤皮肤癌 (MSC) 和非黑色素瘤皮肤癌 (NMSC) 是普遍存在的,在RA发病后诊断的比例更高.
- 在对共变量进行调整后,bDMARD使用与恶性瘤风险增加显著相关 (HR 1.42,95% CI 1.10-1.78).
结论:
- 生物学DMARD与以色列RA患者恶性瘤风险增加有关.
- MSC和NMSC似乎是这种风险增加的关键因素.
- 由于MSC的发病率很高,这表明以色列RA患者可能有这种倾向.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
178
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
178
The JAK-STAT Signaling Pathway
9.0K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.0K
T Cell Types and Functions
1.1K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.1K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
205
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
205
Tumor Immunotherapy
577
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
577
Inflammatory Bowel Disease IV: Pharmacological Management
159
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
159


